Compugen (NASDAQ:CGEN - Get Free Report) was downgraded by StockNews.com from a "buy" rating to a "hold" rating in a report issued on Wednesday.
Separately, Oppenheimer assumed coverage on Compugen in a research report on Monday, January 13th. They set an "outperform" rating and a $4.00 price objective for the company.
Get Our Latest Stock Report on CGEN
Compugen Trading Down 0.6 %
Shares of NASDAQ:CGEN traded down $0.01 during trading on Wednesday, hitting $1.66. 408,357 shares of the stock were exchanged, compared to its average volume of 805,688. The company has a fifty day moving average price of $2.05 and a two-hundred day moving average price of $1.83. The company has a market cap of $148.13 million, a PE ratio of 83.00 and a beta of 2.98. Compugen has a 12-month low of $1.35 and a 12-month high of $3.03.
Compugen (NASDAQ:CGEN - Get Free Report) last announced its quarterly earnings results on Tuesday, March 4th. The biotechnology company reported ($0.07) EPS for the quarter, missing the consensus estimate of $0.07 by ($0.14). The firm had revenue of $1.47 million for the quarter, compared to analysts' expectations of $17.47 million. Compugen had a return on equity of 2.62% and a net margin of 2.67%. Equities research analysts anticipate that Compugen will post -0.03 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Institutional investors have recently modified their holdings of the stock. Commonwealth Equity Services LLC acquired a new position in shares of Compugen during the 4th quarter worth approximately $32,000. Oppenheimer & Co. Inc. raised its holdings in Compugen by 75.9% in the 3rd quarter. Oppenheimer & Co. Inc. now owns 19,350 shares of the biotechnology company's stock valued at $35,000 after acquiring an additional 8,350 shares during the last quarter. Two Sigma Advisers LP raised its holdings in Compugen by 93.6% in the 4th quarter. Two Sigma Advisers LP now owns 35,784 shares of the biotechnology company's stock valued at $55,000 after acquiring an additional 17,300 shares during the last quarter. Jane Street Group LLC acquired a new position in Compugen in the 4th quarter valued at $81,000. Finally, Raymond James Financial Inc. acquired a new position in Compugen in the 4th quarter valued at $103,000. 12.22% of the stock is currently owned by institutional investors and hedge funds.
About Compugen
(
Get Free Report)
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.
Featured Articles
Before you consider Compugen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Compugen wasn't on the list.
While Compugen currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
